ABSTRACT
Objective: Ovarian cancer is one of the most fatal gynaecological malignancies worldwide. In ovarian cancer patients, elevated interleukin-8 (IL-8) level was found in ovarian cyst fluid, ascites, serum, and tumour tissue. This study aimed to determine the relation between ascites' IL-8 level and progression-free survival (PFS) as well as overall survival (OS) in ovarian cancer patients. Material and Methods: This prospective cohort included ovarian cancer patients who underwent primary surgery at Sardjito General Hospital during the 2018-2021 period. Samples were taken from ascites fluid. Outcomes including PFS and OS were recorded at the end of this study. IL-8 level was measured with human cytokine magnetic 10-plex panel for luminex (commercial kit invitrogen). Results: The subjects of this study were 40 ovarian cancer patients. The median follow-up was 24 months. During follow-up, 22 participants (55%) were progression-free. Twenty participants (50%) survived at the end of the study. Patients with high IL-8 level significantly had 2.93 times more risk to develop disease progression (p=0.048) and shorter progression free survival time of 15.4 compared to 27.5 months (p log rank 0.02). High IL-8 also decreased OS time of 19.4 compared to 27.3 months but was not significant (p log rank 0.058). Older age significantly related to low overall survival (0% compared to 58.8%), p=0.003. Conclusion: IL-8 ascites increased the risk of disease progression significantly but did not lower overall survival significantly in ovarian cancer. Older age was found to be unbeneficial for overall survival in ovarian cancer patients.